Skip to main content
SpringerLink
Log in

Anthracycline/docetaxel regimens come at a cost

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Braun M, Jacobs VR, Wagenpfeil S, Sattler D, Harbeck N, Nitz U, Bernard R, Kuhn W, Ihbe-Heffinger A.Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer. Onkologie 32: 473-481, No. 8-9, Sep 2009

  2. Morris PG, Bach PB.Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer. Onkologie 32: 464-466, No. 8-9, Sep 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anthracycline/docetaxel regimens come at a cost. Pharmacoecon. Outcomes News 591, 12 (2009). https://doi.org/10.2165/00151234-200905910-00028

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00028

Keywords

Search

Navigation